Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey Stein(Yale University), Jill Lacy(Smilow Cancer Hospital), Howard S. Höchster(Rutgers, The State University of New Jersey), Ann Marie Boustani(Yale University), Edward James(Yale University), Charles Cha(Memorial Sloan Kettering Cancer Center), Carol Staugaard(Yale University), Jeremy Kortmansky(Yale Cancer Center), Vatsal Patel(Yale University), Ronald R. Salem(Yale University), Li Jia(Shanghai Institutes for Biological Sciences), Bryan Chang(Yale University), Doddamane Indukala(Yale University), Xiangyu Cong(Yale University), Yanhong Deng(Sun Yat-sen University)
Cited by 215
Related Papers
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456